Literature DB >> 33348571

Botulinum Toxin in the Treatment of Headache.

Werner J Becker1.   

Abstract

Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade and has become established as a well-tolerated option for the preventive therapy of chronic migraine. Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of action is quite different from that of the new monoclonal antibodies directed against calcitonin gene-related peptide (CGRP) or its receptor, it is unlikely to be displaced to any major extent by them. Both will likely remain as important tools for patients with chronic migraine and the clinicians assisting them. New types of botulinum toxin selective for sensory pain neurons may well be discovered or produced by recombinant DNA techniques in the coming decade, and this may greatly enhance its therapeutic usefulness. This review summarizes the evolution of botulinum toxin use in headache management over the past several decades and its role in the preventive treatment of chronic migraine and other headache disorders.

Entities:  

Keywords:  CGRP; botulinum toxin; chronic migraine; erenumab; migraine; onabotulinumtoxinA

Mesh:

Substances:

Year:  2020        PMID: 33348571      PMCID: PMC7766412          DOI: 10.3390/toxins12120803

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  62 in total

1.  Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections.

Authors:  A Carruthers; J A Langtry; J Carruthers; G Robinson
Journal:  Headache       Date:  1999-10       Impact factor: 5.887

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature.

Authors:  Brin Freund; Aruna Rao
Journal:  Pain Pract       Date:  2019-04-22       Impact factor: 3.183

Review 4.  On muscle spindles, dystonia and botulinum toxin.

Authors:  R L Rosales; D Dressler
Journal:  Eur J Neurol       Date:  2010-07       Impact factor: 6.089

5.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

6.  Treatment of tension-type headache with botulinum toxin: a pilot study.

Authors:  W J Schulte-Mattler; T Wieser; S Zierz
Journal:  Eur J Med Res       Date:  1999-05-26       Impact factor: 2.175

7.  Onabotulinum toxin A treatment of cervicogenic headache: a randomised, double-blind, placebo-controlled crossover study.

Authors:  Mattias Linde; Knut Hagen; Øyvind Salvesen; Gøril Bruvik Gravdahl; Grethe Helde; Lars Jacob Stovner
Journal:  Cephalalgia       Date:  2011-02-07       Impact factor: 6.292

Review 8.  Interventional Treatment for Post-traumatic Headache.

Authors:  Francis X Conidi
Journal:  Curr Pain Headache Rep       Date:  2016-06

Review 9.  History of Botulinum Toxin Treatment in Movement Disorders.

Authors:  Bahman Jabbari
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2016-11-28

10.  Botulinum toxin in the management of temporomandibular disorders: a systematic review.

Authors:  S Thambar; S Kulkarni; S Armstrong; D Nikolarakos
Journal:  Br J Oral Maxillofac Surg       Date:  2020-03-03       Impact factor: 1.651

View more
  3 in total

Review 1.  Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches.

Authors:  Katarzyna Kępczyńska; Izabela Domitrz
Journal:  Toxins (Basel)       Date:  2022-09-05       Impact factor: 5.075

2.  Editorial on the Special Issue "Botulinum Toxin for the Treatment of Neurological Disorders: Where We Are and Where We Need to Go".

Authors:  Mandar Jog; Alfonso Fasano
Journal:  Toxins (Basel)       Date:  2022-01-05       Impact factor: 4.546

3.  NGF Enhances CGRP Release Evoked by Capsaicin from Rat Trigeminal Neurons: Differential Inhibition by SNAP-25-Cleaving Proteases.

Authors:  Mariia Belinskaia; Tomas Zurawski; Seshu Kumar Kaza; Caren Antoniazzi; J Oliver Dolly; Gary W Lawrence
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.